Article in ACS chemical biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
3 citing papers in PubMed, 6 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
8 authors at 1 institution in 1 country.
Naomi E WidstromUniversity of Minnesota, Department of Biochemistry, Molecular Biology and Biophysics, 420 Washington Avenue SE, Minneapolis, Minnesota 55455, United States.ORCID 0000-0003-3669-5732
Minervo PerezUniversity of Minnesota, Department of Biochemistry, Molecular Biology and Biophysics, 420 Washington Avenue SE, Minneapolis, Minnesota 55455, United States.ORCID 0000-0002-2768-4954
Erica D PrattUniversity of Minnesota, Department of Biochemistry, Molecular Biology and Biophysics, 420 Washington Avenue SE, Minneapolis, Minnesota 55455, United States.ORCID 0000-0002-5868-6020
Jason L HeierUniversity of Minnesota, Department of Biochemistry, Molecular Biology and Biophysics, 420 Washington Avenue SE, Minneapolis, Minnesota 55455, United States.
John F BlankenhornUniversity of Minnesota, Department of Biochemistry, Molecular Biology and Biophysics, 420 Washington Avenue SE, Minneapolis, Minnesota 55455, United States.
Lindsay BreidenbachUniversity of Minnesota, Department of Biochemistry, Molecular Biology and Biophysics, 420 Washington Avenue SE, Minneapolis, Minnesota 55455, United States.
Hannah PetersonUniversity of Minnesota, Department of Biochemistry, Molecular Biology and Biophysics, 420 Washington Avenue SE, Minneapolis, Minnesota 55455, United States.
Laurie L ParkerUniversity of Minnesota, Department of Biochemistry, Molecular Biology and Biophysics, 420 Washington Avenue SE, Minneapolis, Minnesota 55455, United States.ORCID 0000-0002-6234-3346
University of Minnesota · US
Funding
TRAINING GRANT IN MICROBIOLOGY/CANCER RESEARCHT32CA009138 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Scott M. Dehm · 1985 to 2026
$11.3M
Training Grant: Functional Proteomics of AgingT32AG029796 · NIA · UNIVERSITY OF MINNESOTA · PI EDGAR A ARRIAGA, Douglas G Mashek · 2008 to 2026
$6.6M
Biosensor Assay to Screen for Signaling Pathway Inhibition in CancerR01CA182543 · NCI · UNIVERSITY OF MINNESOTA · PI PARKER, LAURIE L. · 2014 to 2018
$2.1M
Multiplexed proteomics-based kinase assay developmentR01GM146386 · NIGMS · UNIVERSITY OF MINNESOTA · PI PARKER, LAURIE L. · 2022 to 2025
$1.5M
Image Overlay for MRI-Guided Needle InsertionsR01CA118371 · NCI · JOHNS HOPKINS UNIVERSITY · PI CARRINO, JOHN ANTHONY · 2007 to 2010
$1.4M
Chromatin Regulation of Double-Strand Break RepairR01CA118357 · NCI · UNIVERSITY OF NEW MEXICO · PI OSLEY, MARY ANN · 2006 to 2010
$1.3M
Fluorescence lifetime-based single fluorophore biosensors of post-translational modification enzyme activityR33CA217780 · NCI · UNIVERSITY OF MINNESOTA · PI PARKER, LAURIE L. · 2017 to 2019
$1.3M
Mechanistic and Biomarker Studies on Cancer Progression and Taxane ResistanceF31CA183571 · NCI · YALE UNIVERSITY · PI MOORE, LAUREN MICHELLE · 2013 to 2016
Bruton's tyrosine kinase (BTK) is a well-documented target for cancer therapeutics due to its role in B-cell signaling pathways. However, inhibitor design is hindered by lack of tools to assess kinase activity. We used in vitro phosphoproteomics to determine BTK's substrate preferences and applied this information to our updated data processing pipeline, KINATEST-ID 2.1.0. This pipeline generates a position-specific scoring matrix for BTK and a list of candidate synthetic substrates, each given a score. Characterization of selected synthetic substrates demonstrated a correlation between KINATEST-ID 2.1.0 score and biochemical performance in in vitro kinase assays. Additionally, by incorporating a known terbium-chelation motif, we adapted synthetic substrates for use in an antibody-free time-resolved terbium luminescence assay. This assay has applications in high-throughput inhibitor screening.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Novel Bruton's Tyrosine Kinase (BTK) Substrates for Time-Resolved Luminescence Assays. · full record | OpenQuestion